NTLA
Intellia Therapeutics, Inc.Company with tickers: NTLA
CIK
1652130
CUSIP
45826J105
Shares Outstanding
139,722,277
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $15,048,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $80,737,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Operating Income | $-100,532,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Net Income | $-96,231,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $-0.81 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $-0.81 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |